Document Detail

Immediate hemodynamic effects of thrombolytic therapy on the ischemic myocardium.
MedLine Citation:
PMID:  8804773     Owner:  NLM     Status:  MEDLINE    
Thrombolytic agents are used to restore coronary artery perfusion and limit the size of a myocardial infarction. The systemic effects of these drugs, streptokinase (SK), urokinase (UK), and recombinant tissue plasminogen activator (rtPA), have been studied extensively. Although their effects on rheology and late myocardial performance have been well-documented to date, there have not been any studies evaluating the acute hemodynamic consequences of thrombolytics immediately after administration. In this report we use an isolated Langendorf rodent heart preparation to evaluate the acute hemodynamic effects of thrombolytic therapy on both the normal and the ischemic myocardium. We quantified performance by documenting cardiac output, coronary blood flow, and blood pressure. Although each thrombolytic agent significantly transiently impairs cardiac performance, differences in effect between the agents were statistically insignificant. This was also the case with both the normal as well as the ischemic myocardium. The results of this study would not support favoring the use of one of these agents over the other with regards to primary myocardial performance.
R L Quigley; M J Khandekar; S S Switzer; M H Salinger
Related Documents :
11234723 - Changing face of acute myocardial infarction in east london: a prospective cohort study...
9825203 - Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroi...
23660183 - Cardiac resynchronization therapy in ckd: a systematic review.
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  Catheterization and cardiovascular diagnosis     Volume:  38     ISSN:  0098-6569     ISO Abbreviation:  Cathet Cardiovasc Diagn     Publication Date:  1996 Jul 
Date Detail:
Created Date:  1996-12-16     Completed Date:  1996-12-16     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7508512     Medline TA:  Cathet Cardiovasc Diagn     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  325-30     Citation Subset:  IM    
Department of Surgery, Guthrie Clinic, Sayre, Pennsylvania 18840, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hemodynamics* / drug effects
Myocardial Ischemia / drug therapy*,  physiopathology*
Rats, Inbred Lew
Recombinant Proteins
Reference Values
Streptokinase / therapeutic use
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use
Urokinase-Type Plasminogen Activator / therapeutic use
Reg. No./Substance:
0/Recombinant Proteins; EC 3.4.-/Streptokinase; EC Plasminogen Activator; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of coronary Palmaz-Schatz stent in the percutaneous treatment of an intracranial carotid artery ...
Next Document:  Coronary plaque morphology affects stent deployment: assessment by intracoronary ultrasound.